News Sentiment

OVID sentiment intelligence

Ovid Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.52 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-6.3% over one week, +9.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend active 9.6% over four weeks
Fair value 31.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 32
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
Stock Titan 6
GlobeNewswire 6
www.marketscreener.com 5
simplywall.st 4
Investing.com Nigeria 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 15
Analyst action 3
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
GuruFocus Direct company coverage

FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc

FEDERATED HERMES, INC. has increased its stake in Ovid Therapeutics Inc. by acquiring an additional 4,166,166 shares at $2.69 per share, bringing its total holding to 7,737,166 shares. This strategic move highlights the investment firm's confidence in Ovid Therapeutics' potential

Tone
Positive 65/100
Event
Deals and strategy
Published
15 Jul 2026 01:12
Source
GuruFocus
Investing.com Nigeria Direct company coverage

Ovid Therapeutics names new chief business officer By Investing.com

Ovid Therapeutics has announced key executive appointments and promotions, including Kevin Norrett as Chief Business Officer and Charles Carter as Chief Financial Officer. The company also promoted Victoria Fort to Chief Strategy Officer and appointed Eliseo Salinas as Executive

Tone
Positive 77/100
Event
Market update
Published
14 Jul 2026 17:12
Source
Investing.com Nigeria
Market source Direct company coverage

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

Ovid Therapeutics (OVID) has appointed Kevin Norrett as Chief Business Officer to lead business and corporate development, as well as strategic partnerships. The company also promoted Charles Carter to CFO and Victoria Fort to Chief Strategy Officer. This news follows a Q1 report

Tone
Positive 66/100
Event
Market update
Published
14 Jul 2026 10:12
Source
Market source
The Globe and Mail Direct company coverage

Ovid Therapeutics appoints Charles Carter as new CFO

Ovid Therapeutics (OVID) has appointed Charles Carter as its new Chief Financial Officer, effective July 6, 2026, following the transition of Jeffrey Rona from his officer roles. Carter, previously Senior Vice President of Finance, will receive a compensation package including a

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 11:11
Source
The Globe and Mail
Investing.com Nigeria Direct company coverage

Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com

This article announces the filing of Form 4 for Ovid Therapeutics Inc. on July 8. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The brief content ref

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:46
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028

Ovid Therapeutics (OVID) has granted its Chief Financial Officer, Charles Ross, 50,000 restricted stock units (RSUs) as equity compensation, with a vesting schedule beginning on July 6, 2027, over two equal annual installments. Each RSU represents a contingent right to receive on

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options

Ovid Therapeutics CFO Charles Ross has filed an initial ownership report, disclosing direct ownership of 44,375 shares of common stock, which includes 34,375 restricted stock units (RSUs) vesting in annual installments from February 20, 2027. He also holds employee stock options

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
O'Dwyer's PR Direct company coverage

PR News | On the Move: Ovid Therapeutics Hires Fort as CSO - Wed., Jul. 8, 2026

Ovid Therapeutics has appointed Victoria Fort as Chief Strategy Officer and Chief of Staff to the CEO. The article also highlights other significant personnel appointments, including RJ Karney as VP, head of government affairs for the National Council of Farmer Cooperatives, and

Tone
Positive 67/100
Event
Market update
Published
08 Jul 2026 17:39
Source
O'Dwyer's PR
Moomoo Direct company coverage

Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID

Ovid Therapeutics announced that Carter has been appointed to a leadership role, bringing over 30 years of experience in finance, strategy, and operational leadership to the company. This strategic addition is expected to bolster Ovid's executive team with seasoned expertise.

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 11:40
Source
Moomoo
Stock Titan Direct company coverage

Ovid adds new business, finance and R&D leaders

Ovid Therapeutics (Nasdaq: OVID) has announced a significant strengthening of its executive leadership team with new appointments and promotions to support its pipeline and next development phase. Kevin Norrett joins as Chief Business Officer, Charles Carter is promoted to Chief

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Stock Titan
GlobeNewswire Direct company coverage

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Ovid Therapeutics Inc. has announced strategic appointments to strengthen its executive leadership team, aiming to support pipeline progress and future development. Key changes include Kevin Norrett as Chief Business Officer, Charles Carter promoted to Chief Financial Officer, El

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 10:39
Source
GlobeNewswire
Stock Titan Direct company coverage

New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant

Ovid Therapeutics (NASDAQ: OVID) has appointed Charles Carter as its new Chief Financial Officer, principal financial officer, principal accounting officer, and secretary, effective July 6, 2026. This follows the mutual agreement for Jeffrey Rona to transition from these roles. R

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Stock Titan
Sahm Direct company coverage

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Ovid Therapeutics (NASDAQ: OVID) has seen its share price rise significantly over the last year, demonstrating potential despite currently operating at a loss. The company has a substantial cash runway of about 3.7 years and a decreasing cash burn rate, along with analyst predict

Tone
Positive 65/100
Event
Balance sheet
Published
04 Jul 2026 06:39
Source
Sahm
www.marketscreener.com Direct company coverage

Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark

Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the Russell Small Cap Comp Growth Benchmark. This move highlights the biopharmaceutical company's growing presence in the market. The company focuses on developing small-molecule medicines for brain conditions and has a pip

Tone
Positive 77/100
Event
Market update
Published
29 Jun 2026 21:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index

Ovid Therapeutics Inc. (NasdaqCM:OVID), a biopharmaceutical company focused on developing therapies for brain conditions, has been added to the Russell 2000 Index. This inclusion is part of several additions to various Russell indices, including the Russell Small Cap Comp Growth,

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 19:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark

Ovid Therapeutics Inc. (NasdaqCM: OVID) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion is part of a series of additions to various Russell indices, including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Index, and R

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 19:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark

Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the Russell 2000 Growth Benchmark. This inclusion follows other recent additions to various Russell and S&P indices, highlighting the company's increasing presence in major market benchmarks. Ovid Therapeutics is a biopharm

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 10:41
Source
www.marketscreener.com
TradingView Direct company coverage

Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID)

This article provides an in-depth financial overview of Ovid Therapeutics Inc. (NASDAQ: OVID), including its current stock price, historical performance, analyst forecasts, and financial estimates. It details the company's market capitalization, earnings, revenue, and EBITDA, alo

Tone
Positive 71/100
Event
Earnings
Published
27 Jun 2026 04:09
Source
TradingView
TradingView Direct company coverage

Ovid Therapeutics Inc. Actuals & Estimates (HAM:1OT)

This article provides financial actuals and estimates for Ovid Therapeutics Inc. (HAM:1OT), a pharmaceutical company. It details analyst forecasts, historical price movements, earnings reports, revenue figures, net income, EBITDA, and employee count, clarifying that the company d

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 02:38
Source
TradingView
TradingView Direct company coverage

OVID Forecast — Price Target — Prediction for 2027

This article provides an in-depth forecast for Ovid Therapeutics Inc. (OVID) stock, including analyst price targets, future earnings, and historical performance. It details the current stock price, market capitalization, volatility, and addresses frequently asked questions regard

Tone
Positive 71/100
Event
Analyst action
Published
26 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Ovid Therapeutics Inc. – NASDAQ:OVID

This article provides the "Price to sales forward" metric for Ovid Therapeutics Inc. (NASDAQ: OVID). It details that the value and change for this metric are not explicitly displayed on the provided snippet. The content primarily comes from TradingView, which aggregates financial

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 15:41
Source
TradingView
TradingView Direct company coverage

Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT)

This article provides financial actuals and estimates for Ovid Therapeutics Inc. (SWB:1OT), including income statement, balance sheet, cash flow data, and valuation metrics. It highlights analyst price forecasts, historical stock performance, upcoming earnings dates, and details

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Ovid Therapeutics Inc. – NASDAQ:OVID

This article provides financial data for Ovid Therapeutics Inc. (NASDAQ: OVID), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot from a financial platform like TradingView, detailing various financial metrics and market information for

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID

This article provides the "Price to earnings forward" value for Ovid Therapeutics Inc. (NASDAQ: OVID). It appears to be a financial data point from TradingView, presented without further analysis or contextual information. The content primarily focuses on the display of this spec

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
TradingKey Direct company coverage

Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Ovid Therapeutics Inc (OVID), detailing its current price momentum score, support and resistance levels for range-bound trading. It also presents a breakdown of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages,

Tone
Positive 64/100
Event
Market update
Published
25 Jun 2026 10:41
Source
TradingKey
www.marketscreener.com Direct company coverage

Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index

Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the S&P Biotechnology Select Industry Index. This news was published on June 21, 2026, at 09:29 pm EDT. The company is a biopharmaceutical firm focused on developing small-molecule medicines for brain conditions.

Tone
Positive 70/100
Event
Market update
Published
22 Jun 2026 01:12
Source
www.marketscreener.com